Basic Stats
| CIK | 827809 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NOVELION THERAPEUTICS INC.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| July 14, 2020 |
Novelion Therapeutics Ceases to be a Reporting Issuer in Canada Exhibit 99.1 Novelion Therapeutics Ceases to be a Reporting Issuer in Canada VANCOUVER, British Columbia, July 8, 2020 – Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) announces that it has ceased to be a reporting issuer under Canadian securities legislation in each of the provinces of Canada as a |
|
| July 14, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 8, 2020 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorporat |
|
| June 12, 2020 |
Novelion Therapeutics Provides Update on Liquidation and Claims Process Exhibit 99.1 Novelion Therapeutics Provides Update on Liquidation and Claims Process VANCOUVER, British Columbia, June 12, 2020 – Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today provides an update on the Company’s voluntary liquidation process (the “Liquidation”) that started on January 16, 202 |
|
| June 12, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 12, 2020 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpora |
|
| March 30, 2020 |
NVLN / NOVELION THERAPEUTICS INC. NT 10-K - - NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2019 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report o |
|
| February 13, 2020 |
NVLN / NOVELION THERAPEUTICS INC. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Novelion Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 21, 2020 |
Novelion Therapeutics Confirms Commencement of Voluntary Liquidation Exhibit 99.1 Novelion Therapeutics Confirms Commencement of Voluntary Liquidation VANCOUVER, British Columbia, January 16, 2020 – Novelion Therapeutics Inc. (“Novelion” or the “Company”) today announced that the implementation of the Company’s voluntary liquidation (the “Liquidation”) commenced at 5:00 p.m. Pacific Time today, January 16, 2020 (the “Effective Date”). As of the Effective Date, Alva |
|
| January 21, 2020 |
NVLN / NOVELION THERAPEUTICS INC. / NB Public Equity K/S - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 16, 2020 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorp |
|
| January 15, 2020 |
NVLN / NOVELION THERAPEUTICS INC. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 10, 2020 |
NVLN / NOVELION THERAPEUTICS INC. / EdgePoint Investment Group Inc. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) NOVELION THERAPEUTICS INC. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) December 20, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 10, 2020 |
Exhibit 99.1 Novelion Therapeutics Announces January 16, 2020 Effective Date for Commencement of Voluntary Liquidation VANCOUVER, British Columbia, January 9, 2020 – Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today announced the definitive date for commencement of implementation of the Company’s voluntary liquidation (the “Liquidation”) as 5:00 p.m. Pacific Time on Ja |
|
| January 10, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2020 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpo |
|
| January 3, 2020 |
Novelion Therapeutics Provides Updates on Voluntary Liquidation and Other Matters Exhibit 99.1 Novelion Therapeutics Provides Updates on Voluntary Liquidation and Other Matters VANCOUVER, British Columbia, January 3, 2020 – Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today provided updates on the status of the Company’s voluntary liquidation and other matters. Background on Company Liquidation As previously announced, at the Company’s 2019 Annual Ge |
|
| January 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incor |
|
| December 11, 2019 |
Novelion Therapeutics Provides Update on Effective Date of Liquidation Exhibit 99.1 Novelion Therapeutics Provides Update on Effective Date of Liquidation VANCOUVER, British Columbia, December 11, 2019 – Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today announced that a hearing date has not yet been scheduled for consideration of the Company’s application materials, filed on November 18, 2019 with the Supreme Court of British Columbia (th |
|
| December 11, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 11, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incor |
|
| November 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 18, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incor |
|
| November 15, 2019 |
QLTI / QLT, Inc. NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2019 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report |
|
| November 5, 2019 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorp |
|
| October 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 7, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpo |
|
| October 8, 2019 |
QLTI / QLT, Inc. DEFA14A - - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 7, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpo |
|
| October 4, 2019 |
QLTI / QLT, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| October 3, 2019 |
QLTI / QLT, Inc. DEF 14A - - DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 2, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpo |
|
| October 3, 2019 |
QLTI / QLT, Inc. DEFA14A - - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 2, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpo |
|
| October 2, 2019 |
NVLN / NOVELION THERAPEUTICS INC. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Novelion Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) September 23, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| September 27, 2019 |
8-K 1 a19-1912138k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 24, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or |
|
| September 27, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Novelion Therapeutics Inc. (Name of Issuer) Common shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) Christopher P. Davis, Esq. Kleinbe |
|
| September 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 24, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Inco |
|
| September 25, 2019 |
QLTI / QLT, Inc. DEFA14A - - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 24, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Inco |
|
| September 20, 2019 |
QLTI / QLT, Inc. PRE 14A - - PRE 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| September 20, 2019 |
NVLN / NOVELION THERAPEUTICS INC. / Healthcare Value Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under The Securities Exchange Act of 1934 (Amendment No. |
|
| September 11, 2019 |
Other Events, Bankruptcy or Receivership UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 9, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incor |
|
| August 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 28, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpo |
|
| August 23, 2019 |
NVLN / NOVELION THERAPEUTICS INC. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Novelion Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) August 14, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| August 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 20, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpo |
|
| August 12, 2019 |
QLTI / QLT, Inc. NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2019 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Fo |
|
| July 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 16, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpora |
|
| July 15, 2019 |
Exhibit 10.1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK -x : In re: : : : : : : Chapter 11 Aegerion Pharmaceuticals, Inc., et al.,1 Case No. 19-11632 (MG) Debtors. (Jointly Administered) -x DEBTORS’ FIRST AMENDED JOINT CHAPTER 11 PLAN Dated: New York, New York July [], 2019 WILLKIE FARR & GALLAGHER LLP Counsel for the Debtors and Debtors in Possession 787 Seventh Avenue New York, |
|
| July 15, 2019 |
Exhibit 10.4 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x In re: : Chapter 11 : Aegerion Pharmaceuticals, Inc., et al.,(1) : Case No. 19-11632 (MG) : Debtors. : (Jointly Administered) x ORDER AUTHORIZING IMPLEMENTATION OF (A) KEY EXECUTIVE INCENTIVE PLAN, AND (B) KEY EMPLOYEE RETENTION PLAN Upon the motion (the “Motion”)(2) of the debtors and debtors in possession in the above-ca |
|
| July 15, 2019 |
Exhibit 10.2 THIS DISCLOSURE STATEMENT IS BEING SUBMITTED FOR APPROVAL TO, BUT HAS NOT BEEN APPROVED BY, THE BANKRUPTCY COURT. THIS IS NOT A SOLICITATION OF ACCEPTANCES OR REJECTIONS OF THE PLAN. ACCEPTANCES OR REJECTIONS OF THE PLAN MAY NOT BE SOLICITED UNTIL A DISCLOSURE STATEMENT HAS BEEN APPROVED BY THE BANKRUPTCY COURT. UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK -x In re : : |
|
| July 15, 2019 |
Exhibit 10.3 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x In re : Chapter 11 : Aegerion Pharmaceuticals, Inc., et al.,(1) : Case No. 19-11632 (MG) : Debtors. : (Jointly Administered) x ORDER: (I) APPROVING DISCLOSURE STATEMENT; (II) ESTABLISHING DATE OF CONFIRMATION HEARING; (III) ESTABLISHING PROCEDURES FOR SOLICITATION AND TABULATION OF VOTES TO ACCEPT OR REJECT PLAN, INCLUDING |
|
| July 15, 2019 |
Financial Statements and Exhibits, Bankruptcy or Receivership UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 11, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpora |
|
| July 5, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 3, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorporat |
|
| July 1, 2019 |
Interim Shared Services Agreements Order. Exhibit 10.2 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x In re: : Chapter 11 : Aegerion Pharmaceuticals, Inc., et al.,(1) : Case No. 19-11632 (MG) : Debtors. : (Jointly Administered) x INTERIM ORDER (I) AUTHORIZING THE DEBTORS TO CONTINUE OPERATING UNDER THE TERMS OF THE SHARED SERVICES AGREEMENTS, AS AMENDED, AND (II) GRANTING RELATED RELIEF Upon the motion (the “Motion”)(2) of |
|
| July 1, 2019 |
Exhibit 10.1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x In re : Chapter 11 : Aegerion Pharmaceuticals, Inc., et al.,(1) : Case No. 19-11632 (MG) : Debtors. : (Jointly Administered) x FINAL ORDER (I) AUTHORIZING DEBTORS TO OBTAIN POSTPETITION FINANCING PURSUANT TO SECTION 364 OF THE BANKRUPTCY CODE, (II) AUTHORIZING THE USE OF CASH COLLATERAL PURSUANT TO SECTION 363 OF THE BANKR |
|
| July 1, 2019 |
Financial Statements and Exhibits, Bankruptcy or Receivership 8-K 1 a19-1231618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Othe |
|
| July 1, 2019 |
Exhibit 10.3 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK x In re: : Chapter 11 : Aegerion Pharmaceuticals, Inc., et al.,(1) : Case No. 19-11632 (MG) : Debtors. : (Jointly Administered) x ORDER: (A) APPROVING AND AUTHORIZING CERTAIN PLAN INVESTOR PROTECTIONS; AND (B) GRANTING RELATED RELIEF Upon the motion (the “Motion”)(2) of the debtors in the above-captioned cases (the “Debtors” |
|
| June 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 20, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpora |
|
| June 20, 2019 |
Please see PDF for document reference. Please see PDF for document reference. |
|
| June 20, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Novelion Therapeutics Inc. (Name of Issuer) Common shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) Christopher P. Davis, Esq. Kleinbe |
|
| June 20, 2019 | ||
| June 20, 2019 |
KLEINBERG, KAPLAN, WOLFF & COHEN, P.C. Hearing Date: June 27, 2019 Dov Kleiner Hearing Time: 9:00 a.m. 551 Fifth Avenue, 18th Floor New York, NY 10176 (212) 986-6000 Whitefort Capital Master Fund, LP UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK -x In re Aegerion Pharmaceuticals, Inc., et al., Debtors. : : : : : : : Chapter 11 Case No. 19-11632 (MG) (Jointly Administered) -x LIMITED |
|
| June 20, 2019 |
Please see PDF for document reference. Please see PDF for document reference. |
|
| May 31, 2019 |
NVLN / NOVELION THERAPEUTICS INC. / JFL Capital Management, LLC - NVLN 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Novelion Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67001K202 (CUSIP Number) c/o Norton Rose Fulbright, 1800-510 West Georgia Street, Vancouver, BC V6B 0M3 Canada (Name, Address and Telephone Number of Person Authorized |
|
| May 24, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Novelion Therapeutics Inc. (Name of Issuer) Common shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) Christopher P. Davis, Esq. Kleinbe |
|
| May 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorporat |
|
| May 21, 2019 |
EXHIBIT 99.1 Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion · Transaction is result of comprehensive capital structure and strategic review conducted independently by both Novelion’s and Aegerion’s Boards of Directors · Aegerion will continue to make av |
|
| May 21, 2019 |
Exhibit 99.2 Disclaimer The following financial projections and forecasts (the “Projections”) were not prepared with a view toward public disclosure or compliance with the guidelines of the Securities and Exchange Commission or the guidelines established by the Public Company Accounting Oversight Board and should not be relied upon to make an investment decision with respect to Novelion Therapeuti |
|
| May 21, 2019 |
Plan Funding Agreement, dated May 20, 2019 by and among, Aegerion and the Plan Investor. EXHIBIT 10.2 Execution Version AEGERION PHARMACEUTICALS, INC. AND AMRYT PHARMA PLC PLAN FUNDING AGREEMENT May 20, 2019 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 5 Section 1.1. Definitions 5 Section 1.2. Other Definitions 17 ARTICLE II. ACQUISITION; ISSUANCE OF CLOSING SHARES 18 Section 2.1. Acquisition 18 Section 2.2. Transaction Consideration 19 ARTICLE III. THE CLOSING 19 Section 3.1. The Cl |
|
| May 21, 2019 |
EXHIBIT 10.3 EXECUTION VERSION Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]” AMENDMENT TO SHARED SERVICES AGREEMENTS This Amendment to Shared Services Agreements (the “Amendment”), dated as |
|
| May 21, 2019 |
EXHIBIT 10.1 Execution Version RESTRUCTURING SUPPORT AGREEMENT This Restructuring Support Agreement (as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms set forth herein, this “Agreement”), dated as of May 20, 2019, is made by and among: (a) Aegerion Pharmaceuticals, Inc. (“Aegerion”) and each of its subsidiaries that are party hereto (collective |
|
| May 15, 2019 |
SC 13G/A 1 p19-1097sc13ga.htm NOVELION THERAPEUTICS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Novelion Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) May 15, 2019 (Date of event which requires filing of this statement) Check t |
|
| May 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Commission File Number 000-17082 Novelion Therapeutics Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-0455702 (State or other |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorporati |
|
| May 7, 2019 |
a102keipplandocument Exhibit 10.2 NOVELION THERAPEUTICS INC. AMENDED AND RESTATED KEY EXECUTIVE INCENTIVE PLAN ARTICLE 1. Introduction. The purpose of the Plan is to provide incentives for Participants to promote exceptional performance by Novelion Therapeutics Inc. (the “Company”), to reinforce restructuring objectives that maximize value to all stakeholders, and to maintain and reinforce the imp |
|
| May 7, 2019 |
a101redactedrecordatilic Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| May 7, 2019 |
Novelion Therapeutics Reports First Quarter 2019 Financial Results Exhibit 99.1 Novelion Therapeutics Reports First Quarter 2019 Financial Results – Company reiterates 2019 guidance of total net revenues between $160.0 and $175.0 million, including approximately $30.0 million of licensing revenues VANCOUVER, British Columbia, and CAMBRIDGE, MA, May 7, 2019 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commerc |
|
| April 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. |
|
| April 2, 2019 |
begin 644 novelionex992-040219.pdf M)5!$1BTQ+C4-)>+CS],-"C,W(# @;V)J#3P\+TQI;F5AR#N7Q!W&8BU',2* K$20"P=$.$*)(23 M08J3@ 17"Y#@^0HR:@Z0B#<"L1J!A'\L Q,CPQ:010R,I!'&<]] P@P #ST M#ST-"F5N9'-TMJE+4N*,F\V;;S0\]JAX[B3;>>'S):RVS-F5O\,(J!@;VCHX.!(;T# M3)E#*'9DBK&BHZ,!V1JP$QB]A("T,!"+@T7"&/@9K00B!!9(-)0\N,*XHIF% M380[0KS2X()B4W?K^0:WO3L8UC9^X&5. KIZ20/$G2(,C!G3@30C$'>!C6(L M+X#P&<4! @P ?#A!6PT*96YD%LP(# @-C$ |
|
| April 2, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Novelion Therapeutics Inc. (Name of Issuer) Common shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) Christopher P. Davis, Esq. Kleinbe |
|
| April 2, 2019 |
Please see PDF for document reference Please see PDF for document reference |
|
| March 29, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Novelion Therapeutics Inc. (Name of Issuer) Common shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) Christopher P. Davis, Esq. Kleinber |
|
| March 29, 2019 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Common stock without par value, of Novelion Therapeutics Inc. dated as of the date hereof is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1( |
|
| March 15, 2019 |
Exhibit 10.40 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 27th day of November, 2017, between Novelion Services USA, Inc., a Delaware corporation (the “Company”), and Dr. Murray Willis Stewart (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on or before November 27, 2017 (th |
|
| March 15, 2019 |
Exhibit 21.1 SUBSIDIARIES OF NOVELION THERAPEUTICS INC. AS OF DECEMBER 31, 2018 Entity Name Jurisdiction of Organization or Incorporation Aegerion Pharmaceuticals, Inc. Delaware Aegerion Pharmaceuticals Ltd. Bermuda Aegerion Pharmaceuticals (Canada) Ltd. Canada Aegerion Pharmaceuticals Holdings, Inc. Delaware Aegerion Argentina S.R.L. Argentina Aegerion Pharmaceuticals K.K. Japan Aegerion Securiti |
|
| March 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-17082 Novelion Therapeutics Inc. |
|
| March 15, 2019 |
NOVELION THERAPEUTICS INC. KEY EXECUTIVE INCENTIVE PLAN Exhibit 10.52 NOVELION THERAPEUTICS INC. KEY EXECUTIVE INCENTIVE PLAN ARTICLE 1. Introduction. The purpose of the Plan is to provide incentives for Participants to promote exceptional performance by Novelion Therapeutics Inc. (the “Company”), to reinforce restructuring objectives that maximize value to all stakeholders, and to maintain and reinforce the importance of financial and operational mile |
|
| March 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpor |
|
| March 14, 2019 |
Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Exhibit 99.1 Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results – Company achieves FY 2018 total net revenues of $130.4 million – FY 2018 operating expenses reduced by $27.2 million, or 18.4% VANCOUVER, British Columbia, and Cambridge, MA, March 14, 2019 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializi |
|
| February 14, 2019 |
NVLN / NOVELION THERAPEUTICS INC. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1 )* Novelion Therapeutics Inc. (Name of Issuer) Common shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 13, 2019 |
NVLN / NOVELION THERAPEUTICS INC. / EdgePoint Investment Group Inc. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* NOVELION THERAPEUTICS INC. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Novelion Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorp |
|
| February 6, 2019 |
Exhibit 99.1 Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan · Out-licensing of commercialization rights allows for significant operating expense savings · Upfront payments improve near-term liquidity Vancouver, British Columbia, February 6, 2019 — Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of |
|
| February 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 31, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction (Commissi |
|
| December 27, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 17, 2018 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the foregoing Statement on Schedule 13G/A with respect to the shares of Common Stock of Novelion Therapeutics Inc., and any further amendments thereto executed by each and any of the undersigned, shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Se |
|
| December 17, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / NB Public Equity K/S - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv509190sc13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Novelion Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67001K202 (CUSIP Number) November 9, 2018 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designat |
|
| December 3, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / Healthcare Value Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under The Securities Exchange Act of 1934 (Amendment No. |
|
| November 29, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Novelion Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) November 19, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to wh |
|
| November 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incor |
|
| November 20, 2018 |
Exhibit 99.1 Novelion Therapeutics Announces Leadership Change Novelion General Counsel Benjamin Harshbarger Appointed as Interim Chief Executive Officer (CEO) Vancouver, British Columbia, November 20, 2018 — Novelion Therapeutics Inc. (NASDAQ:NVLN), today announced that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan |
|
| November 20, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incor |
|
| November 19, 2018 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the foregoing Statement on Schedule 13G with respect to the shares of Common Stock of Novelion Therapeutics Inc., and any further amendments thereto executed by each and any of the undersigned, shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Secu |
|
| November 19, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / NB Public Equity K/S - SCHEDULE 13G Passive Investment SC 13G 1 tv507580sc13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Novelion Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67001K202 (CUSIP Number) January 9, 2018 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rul |
|
| November 13, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 Commission File Number 000-17082 Novelion Therapeutics Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-0455702 (State or o |
|
| November 13, 2018 |
Exhibit 10.3 THE INDEBTEDNESS AND OTHER OBLIGATIONS OF THE BORROWER UNDER OR EVIDENCED HEREBY WITH RESPECT TO THE ROLL UP LOANS AND THE LIENS AND SECURITY INTERESTS SECURING THE ROLL UP LOANS ARE SUBORDINATED PURSUANT TO THE TERMS AND CONDITIONS OF THE NOVELION SUBORDINATION AGREEMENT BRIDGE CREDIT AGREEMENT Dated as of November 8, 2018 Among AEGERION PHARMACEUTICALS, INC., as Borrower, THE LENDER |
|
| November 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorp |
|
| November 9, 2018 |
Novelion Therapeutics Reports Third Quarter 2018 Financial Results Exhibit 99.1 Novelion Therapeutics Reports Third Quarter 2018 Financial Results VANCOUVER, British Columbia, November 9, 2018 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for the third quarter and nine months end |
|
| November 9, 2018 |
Schedule 13D Amendment No. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Novelion Therapeutics Inc. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0 |
|
| November 8, 2018 |
Exhibit 99.2 Business Update November 2018 Proprietary and Confidential. Copyright © 2018 Novelion Therapeutics Inc. All rights reserved. Special Cautionary Statements about this Presentation This presentation includes statements about Novelion’s and Aegerion’s future plans and opportunities. Readers are cautioned that Novelion’s and Aegerion’s ability to pursue and execute on such plans and oppor |
|
| November 8, 2018 |
Subordination Agreement made as of November 8, 2018. EX-10.3 4 a18-398051ex10d3.htm EX-10.3 Exhibit 10.3 EXECUTION VERSION SUBORDINATION AGREEMENT This Subordination Agreement (the “Agreement”) is made as of November 8, 2018, by and between CANTOR FITZGERALD SECURITIES, as administrative agent and collateral agent for the New Lenders (in such capacities, together with any successor administrative agent and collateral agent, “Senior Agent”), the sign |
|
| November 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorp |
|
| November 8, 2018 |
EX-99.1 5 a18-398051ex99d1.htm EX-99.1 Exhibit 99.1 Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update · New Aegerion loan facility, provided by existing bondholders, strengthens balance sheet and is expected to provide bridge to a potential comprehensive long-term capital restructuring · Company expects to achieve positive cash flow at Aegerion |
|
| November 8, 2018 |
Bridge Credit Agreement, dated November 8, 2018 Exhibit 10.1 THE INDEBTEDNESS AND OTHER OBLIGATIONS OF THE BORROWER UNDER OR EVIDENCED HEREBY WITH RESPECT TO THE ROLL UP LOANS AND THE LIENS AND SECURITY INTERESTS SECURING THE ROLL UP LOANS ARE SUBORDINATED PURSUANT TO THE TERMS AND CONDITIONS OF THE NOVELION SUBORDINATION AGREEMENT BRIDGE CREDIT AGREEMENT Dated as of November 8, 2018 Among AEGERION PHARMACEUTICALS, INC., as Borrower, THE LENDER |
|
| November 8, 2018 |
Exhibit 10.2 Execution Version AMENDMENT NO. 1 TO AND CONSENT UNDER THE AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This Amendment No. 1 to and Consent Under the Amended and Restated Loan and Security Agreement (this “Amendment”), dated as of November 8, 2018, is entered into by and among Aegerion Pharmaceuticals, Inc., a Delaware corporation (“Borrower”), Aegerion Pharmaceuticals Holdings, I |
|
| September 25, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 24, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Inco |
|
| September 20, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 17, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Inco |
|
| September 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 13, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Inco |
|
| August 23, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 21, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpo |
|
| August 23, 2018 |
EX-99.1 2 a18-210941ex99d1.htm EX-99.1 Exhibit 99.1 Novelion Therapeutics Announces Next Phase of Operational Improvements Once fully implemented, plans expected to reduce annual costs by approximately $35 million Vancouver, British Columbia, August 23, 2018 — Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living |
|
| August 23, 2018 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Novelion Therapeutics, Inc. |
|
| August 23, 2018 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Novelion Therapeutics Inc. (Name of Issuer) Common shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) August 14, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| August 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpor |
|
| August 7, 2018 |
Exhibit 99.1 Novelion Therapeutics Reports Second Quarter 2018 Financial Results Following recent marketing approval in both generalized and partial lipodystrophy indications, European launch of MYALEPTA® has commenced VANCOUVER, British Columbia, August 7, 2018 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for indivi |
|
| August 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 7, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpor |
|
| August 7, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 Commission File Number 000-17082 Novelion Therapeutics Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-0455702 (State or other |
|
| August 7, 2018 |
AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this “Amendment”) is entered into as of April 20, 2018 by and between Novelion Services USA, Inc., a Delaware corporation (the “Company”), and Dr. Murray Willis Stewart (the “Executive”). WHEREAS, Executive and Company are parties to an Employment Agreement, dated as of November 27, 2017 (the “Employment Agreeme |
|
| July 26, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / Healthcare Value Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under The Securities Exchange Act of 1934 (Amendment No. |
|
| July 19, 2018 |
QLTI / QLT, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 16, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpora |
|
| July 19, 2018 |
AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this “Amendment”) is entered into as of April 20, 2018 by and between Novelion Services USA, Inc., a Delaware corporation (the “Company”), and Michael D. Price (the “Executive”). WHEREAS, Executive and Company are parties to an Employment Agreement, dated as of November 27, 2017 (the “Employment Agreement”); and |
|
| July 19, 2018 |
AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.1 2 a101amendmentasofjuly2018.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this “Amendment”) is entered into as of July 16, 2018 by and between Novelion Services USA, Inc., a Delaware corporation (the “Company”), and Michael D. Price (the “Executive”). WHEREAS, Executive and Company are parties to an Employment Agreement, dated as of |
|
| July 16, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / EdgePoint Investment Group Inc. Activist Investment SCHEDULE 13D Under the Securities Exchange Act of 1934 AMENDMENT NO. 1 Novelion Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 67001K202 (CUSIP Number) Sayuri Childs, Chief Compliance Officer c/o EdgePoint Investment Group Inc. 150 Bloor Street West, Suite 500 Toronto, Ontario M5S 2X9 Canada (Name, Address and Telephone Number of Person Authorized to Receive Notice |
|
| July 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a‑101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| July 3, 2018 |
Exhibit 99.1 Novelion Therapeutics Appoints Mark Corrigan, MD as Executive Chair of the Board of Directors Chief Operating Officer Jeff Hackman Appointed as Interim Chief Executive Officer (CEO) Vancouver, British Columbia, July 3, 2018 - Novelion Therapeutics Inc. (NASDAQ:NVLN), today announced that Mark Corrigan, M.D. has been appointed as Executive Chair of the Board of Directors. As Executive |
|
| July 3, 2018 |
QLTI / QLT, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 2, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorporat |
|
| June 27, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / EdgePoint Investment Group Inc. Activist Investment SCHEDULE 13D Under the Securities Exchange Act of 1934 Novelion Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 67001K202 (CUSIP Number) Sayuri Childs, Chief Compliance Officer c/o EdgePoint Investment Group Inc. 150 Bloor Street West, Suite 500 Toronto, Ontario M5S 2X9 Canada (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communicat |
|
| June 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorporat |
|
| June 11, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / Healthcare Value Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 10, 2018 |
Novelion Therapeutics Reports First Quarter 2018 Financial Results Exhibit 99.1 Novelion Therapeutics Reports First Quarter 2018 Financial Results VANCOUVER, British Columbia, May 10, 2018 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for the first quarter ended March 31, 2018 an |
|
| May 10, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorporat |
|
| May 10, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 Commission File Number 000-17082 Novelion Therapeutics Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-0455702 (State or other |
|
| April 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. |
|
| March 20, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / Broadfin Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| March 19, 2018 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d−1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Novelion Therapeutics Inc. |
|
| March 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Novelion Therapeutics Inc. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 With a copy |
|
| March 16, 2018 |
Exhibit 10.36 NOVELION THERAPEUTICS INC. AMENDED AND RESTATED NOVELION 2017 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AWARD AGREEMENT Novelion Therapeutics Inc. (the “Company”), pursuant to its Amended and Restated 2017 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee”), an award |
|
| March 16, 2018 |
Exhibit 10.37 NOVELION THERAPEUTICS INC. AMENDED AND RESTATED NOVELION 2017 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AWARD AGREEMENT (Executives) Novelion Therapeutics Inc. (the “Company”), pursuant to its Amended and Restated 2017 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee |
|
| March 16, 2018 |
Exhibit 10.41 November 30, 2017 BY EMAIL PERSONAL AND CONFIDENTIAL Greg Perry Re: Resignation Agreement Dear Greg: This letter confirms your resignation from employment with Novelion Services, USA, Inc. (the “Company”) and proposes an agreement (the “Agreement”) between you and the Company. The purpose of this Agreement is to establish an amicable arrangement for ending your employment relationshi |
|
| March 16, 2018 |
Exhibit 10.34 NOVELION THERAPEUTICS INC. AMENDED AND RESTATED NOVELION 2017 EQUITY INCENTIVE PLAN STOCK OPTION AWARD GRANT NOTICE AND STOCK OPTION AWARD AGREEMENT (Employees) Novelion Therapeutics Inc. (the “Company”), pursuant to its Amended and Restated 2017 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee”), an award (“Awar |
|
| March 16, 2018 |
Exhibit 10.40 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 27th day of November, 2017, between Novelion Services USA, Inc., a Delaware corporation (the “Company”), and Michael Price (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on November 27, 2017 (the “Commencement Date”) |
|
| March 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-17082 Novelion Therapeutics Inc. |
|
| March 16, 2018 |
Exhibit 10.39 November 8, 2017 PERSONAL AND CONFIDENTIAL Mary Szela 6 Bannockburn Ct Bannockburn, IL 60015 Re: Resignation Agreement Dear Mary: This letter confirms your separation from employment with Novelion Services, USA, Inc. (the “Company”) and proposes an agreement (the “Agreement”) between you and the Company. The purpose of this Agreement is to establish an amicable arrangement for ending |
|
| March 16, 2018 |
SUBSIDIARIES OF NOVELION THERAPEUTICS INC. AS OF DECEMBER 31, 2017 Exhibit 21.1 SUBSIDIARIES OF NOVELION THERAPEUTICS INC. AS OF DECEMBER 31, 2017 Entity Name Jurisdiction of Organization or Incorporation Aegerion Pharmaceuticals, Inc. Delaware Aegerion Pharmaceuticals Ltd. Bermuda Aegerion Pharmaceuticals (Canada) Ltd. Canada Aegerion Pharmaceuticals Holdings, Inc. Delaware Aegerion Argentina S.R.L. Argentina Aegerion Pharmaceuticals K.K. Japan Aegerion Securiti |
|
| March 16, 2018 |
Exhibit 10.35 NOVELION THERAPEUTICS INC. AMENDED AND RESTATED NOVELION 2017 EQUITY INCENTIVE PLAN STOCK OPTION AWARD GRANT NOTICE AND STOCK OPTION AWARD AGREEMENT (Executives) Novelion Therapeutics Inc. (the “Company”), pursuant to its Amended and Restated 2017 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee”), an award (“Awa |
|
| March 16, 2018 |
Exhibit 10.38 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 31st day of October, 2017, between Novelion Services USA, Inc., a Delaware corporation (the “Company”), and Jeffrey Hackman (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on or before November 1, 2017 (the “Commencem |
|
| March 16, 2018 |
Exhibit 10.33 NOVELION THERAPEUTICS INC. AMENDED AND RESTATED NOVELION 2017 EQUITY INCENTIVE PLAN STOCK OPTION AWARD GRANT NOTICE AND STOCK OPTION AWARD AGREEMENT (Directors) Novelion Therapeutics Inc. (the “Company”), pursuant to its Amended and Restated 2017 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee”), an award (“Awar |
|
| March 15, 2018 |
QLTI / QLT, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 15, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpor |
|
| March 15, 2018 |
Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Exhibit 99.1 Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results • Novelion reports 2017 total net revenues of $138.4 million, in line with previously stated guidance • Plans underway to address capital structure and advance metreleptin development program VANCOUVER, British Columbia, March 15, 2018 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical comp |
|
| March 15, 2018 |
Exhibit 99.1 Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital Aegerion strengthens balance sheet and liquidity, positioning company for ongoing capital structure review Vancouver, British Columbia, March 15, 2018 — Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care |
|
| March 15, 2018 |
EX-10.1 2 a18-83801ex10d1.htm EX-10.1 Exhibit 10.1 THE INDEBTEDNESS AND OTHER OBLIGATIONS OF AEGERION PHARMACEUTICALS, INC. (“BORROWER”) UNDER OR EVIDENCED HEREBY ARE SUBORDINATED AND SUBJECT TO THE TERMS AND CONDITIONS OF THE SUBORDINATION AGREEMENT, DATED AS OF MARCH 15, 2018, AMONG BORROWER, WILMINGTON SAVINGS FUND SOCIETY FSB, AS AGENT, AS A JUNIOR CREDITOR, THE OTHER JUNIOR CREDITORS PARTY TH |
|
| March 15, 2018 |
Exhibit 10.2 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of March 15, 2018, between NOVELION THERAPEUTICS INC., a corporation incorporated under the laws of British Columbia (“Lender”), and AEGERION PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), provides for the amendment and restatement of the Orig |
|
| March 15, 2018 |
Exhibit 10.3 SUBORDINATION AGREEMENT This Subordination Agreement (the “Agreement”) is made as of March 15, 2018, by and between the signatories hereto under the heading “JUNIOR CREDITOR” (each a “Junior Creditor” and collectively, the “Junior Creditors”), and NOVELION THERAPEUTICS INC., a corporation organized under the laws of British Columbia (“Senior Creditor”). Recitals A. Aegerion Pharmaceut |
|
| March 15, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 15, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 98-0455702 (State or Other Jurisdiction of Incorpor |
|
| February 14, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Novelion Therapeutics Inc. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) December 31, 2017 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / SCOPIA CAPITAL MANAGEMENT LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / EdgePoint Investment Group Inc. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NOVELION THERAPEUTICS INC. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 13, 2018 |
NVLN / NOVELION THERAPEUTICS INC. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Novelion Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 31, 2018 |
Exhibit 99.1 Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals Financial terms of the sentence align with previous company filings Vancouver, British Columbia, January 30, 2018 ? Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that |
|
| January 31, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 a18-502718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 30, 2018 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jur |
|
| December 8, 2017 |
NVLN / NOVELION THERAPEUTICS INC. / EdgePoint Investment Group Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NOVELION THERAPEUTICS INC. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) November 30, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| December 6, 2017 |
Exhibit 24.1 POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Benjamin Harshbarger, Gregory Perry, Jennifer Fitzpatrick, and Stuart Cable, signing singly, as the undersigned?s true and lawful attorneys-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securities and Exchange Commission (the ?SEC?) a Form ID, |
|
| December 4, 2017 |
Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer Exhibit Exhibit No. 99.1 Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer Vancouver, British Columbia, December 4, 2017 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Michael Price as senior |
|
| December 4, 2017 |
QLTI / QLT, Inc. 8-K (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 28, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Inc |
|
| November 29, 2017 |
Exhibit 24.1 POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Benjamin Harshbarger, Gregory Perry, Jennifer Fitzpatrick, and Stuart Cable, signing singly, as the undersigned?s true and lawful attorneys-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securities and Exchange Commission (the ?SEC?) a Form ID, |
|
| November 16, 2017 |
QLTI / QLT, Inc. 8-K/A (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of In |
|
| November 9, 2017 |
QLTI / QLT, Inc. 8-K (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Inco |
|
| November 9, 2017 |
Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change Exhibit Exhibit 99.1 Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change ? Company Reiterates FY 2017 Guidance for Total Net Revenues of $135-$145 million ? Company Announces Leadership Change and Search for Chief Executive Officer VANCOUVER, British Columbia, November 9, 2017 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company de |
|
| November 9, 2017 |
Novelion USA Services, Inc. 2711 Centerville Road Suite 400 Wilmington, DE 19808 Exhibit 10.1 Novelion USA Services, Inc. 2711 Centerville Road Suite 400 Wilmington, DE 19808 August 31, 2017 Remi Alexis Menes 303 Third Street, Unit 327 Cambridge, MA 02142 Dear Remi: The purpose of this letter agreement (the “Agreement”) is to confirm the agreement between you and the Company concerning your separation from employment and severance benefits. As we discussed, your employment wit |
|
| November 9, 2017 |
Exhibit 10.2 September 13, 2017 STRICTLY PERSONAL AND CONFIDENTIAL Gregory Perry 500 Washington Road Barrington, RI 02806 Dear Greg: Re: Amendment to your Employment Agreement Further to our recent discussions, this letter sets out our proposal to amend the terms of your employment with Novelion Services USA, Inc. (“Novelion Services”). This letter is referred to as the Amendment Agreement and is |
|
| November 9, 2017 |
QLTI / QLT, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 Commission File Number 001-34921 Novelion Therapeutics Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other ju |
|
| November 1, 2017 |
Exhibit 24.1 POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Benjamin Harshbarger, Gregory Perry, Jennifer Fitzpatrick, and Stuart Cable, signing singly, as the undersigned?s true and lawful attorneys-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securities and Exchange Commission (the ?SEC?) a Form ID, |
|
| October 31, 2017 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Inco |
|
| October 31, 2017 |
Exhibit Exhibit No. 99.1 Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer Vancouver, British Columbia, October 31, 2017 - Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Jeffrey Hackma |
|
| October 4, 2017 |
Exhibit 24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Benjamin Harshbarger, Gregory Perry, Jennifer Fitzpatrick, and Stuart Cable, signing singly, as the undersigned?s true and lawful attorneys-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U. |
|
| September 22, 2017 |
Proposed Final Judgment, dated September 22, 2017. Exhibit 10.3 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS SECURITIES AND EXCHANGE COMMISSION, Plaintiff, C.A. No. - ( ) v. AEGERION PHARMACEUTICALS, INC., Defendant. FINAL JUDGMENT AS TO DEFENDANT AEGERION PHARMACEUTICALS, INC. The Securities and Exchange Commission having filed a Complaint and Defendant Aegerion Pharmaceuticals, Inc. (“Aegerion”) having entered a general appearance; con |
|
| September 22, 2017 |
Corporate Integrity Agreement, dated September 22, 2017. Exhibit 10.5 CORPORATE INTEGRITY AGREEMENT BETWEEN THE OFFICE OF INSPECTOR GENERAL OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND AEGERION PHARMACEUTICALS, INC. I. PREAMBLE Aegerion Pharmaceuticals, Inc. (Aegerion) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote |
|
| September 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 22, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorporati |
|
| September 22, 2017 |
Civil Settlement Agreement, dated September 22, 2017. Exhibit 10.2 SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is entered into among the following Parties (“Parties”): the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General (“OIG-HHS”) of the Department of Health and Human Services (“HHS”); the Defense Health Agency (“DHA”), acting on behalf of the TRICARE |
|
| September 22, 2017 |
Consent Decree of Final Injunction, dated September 22, 2017. Exhibit 10.6 IN THE UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS UNITED STATES OF AMERICA, Plaintiff, v. AEGERION PHARMACEUTICALS, INC., Civil Action No. a corporation and DR. CHARLES M. GERRITS, an individual, Defendants. CONSENT DECREE OF PERMANENT INJUNCTION Plaintiff, the United States of America, by its undersigned attorneys, having filed a complaint for permanent injunctive relief |
|
| September 22, 2017 |
Plea Agreement, dated September 22, 2017. Exhibit 10.1 U.S. Department of Justice William D. Weinreb Acting United States Attorney District of Massachusetts Main Reception: (617) 748-3100 John Joseph Moakley United States Courthouse 1 Courthouse Way Suite 9200 Boston, Massachusetts 02210 September 22, 2017 Joshua S. Levy Ropes & Gray Prudential Tower 800 Boylston Street Boston, MA 02199-3600 Re: United States v. Aegerion Pharmaceuticals, |
|
| September 22, 2017 |
Deferred Prosecution Agreement, dated September 22, 2017. Exhibit 10.4 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS ) UNITED STATES OF AMERICA ) ) v. ) Criminal No. ) AEGERION PHARMACEUTICALS, INC., ) ) Defendant. ) ) DEFERRED PROSECUTION AGREEMENT 1. William D. Weinreb, Acting United States Attorney for the District of Massachusetts (by Assistant U.S. Attorneys Young Paik and Kriss Basil) (the “Office”); the United States Department of Justice |
|
| September 11, 2017 |
Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors Exhibit Exhibit No. 99.1 Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors Vancouver, British Columbia, September 11, 2017 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Suzanne Bruhn, Ph.D. to its board of directors, effectiv |
|
| September 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorporatio |
|
| August 31, 2017 |
Qlt 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 28, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incor |
|
| August 8, 2017 |
Qlt 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorp |
|
| August 8, 2017 |
Novelion Therapeutics Reports Second Quarter 2017 Financial Results Exhibit Exhibit 99.1 Novelion Therapeutics Reports Second Quarter 2017 Financial Results ? MYALEPT? Total Net Revenues Increase 28% Over Prior Quarter, Excluding One-Time Adjustments ? Global Expansion Plans for Metreleptin Opportunity Underway ? Company Updates Guidance for FY 2017 Total Net Revenues ? Conference call to be held today at 8:30 a.m. ET VANCOUVER, British Columbia, August 8, 2017 - |
|
| August 8, 2017 |
QLTI / QLT, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Commission File Number 001-34921 Novelion Therapeutics Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdi |
|
| August 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Novelion Therapeutics Inc. (Name of Issuer) Common Stock, without par valuse (Title of Class of Securities) 67001K103 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 With a cop |
|
| August 2, 2017 |
Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors EX-99.1 2 a080217pressreleasexexhib.htm EXHIBIT 99.1 Exhibit 99.1 Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors Vancouver, British Columbia, August 2, 2017 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark DiPaolo to its board o |
|
| August 2, 2017 |
Qlt 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 31, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorpo |
|
| August 2, 2017 |
Exhibit 24.1 POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Benjamin Harshbarger, Gregory Perry, Janet Grove and Jennifer Fitzpatrick, signing singly, as the undersigned?s true and lawful attorneys-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securities and Exchange Commission (the ?SEC?) a Form ID, in |
|
| July 31, 2017 |
Exhibit 99.1 AMENDED AND RESTATED NOVELION 2017 EQUITY INCENTIVE PLAN (DATED APRIL 25, 2013, AMENDED AND RESTATED EFFECTIVE NOVEMBER 29, 2016, FURTHER AMENDED AND RESTATED EFFECTIVE DECEMBER 1, 2016 AND FURTHER AMENDED AND RESTATED EFFECTIVE APRIL 26, 2017) 1. PURPOSE OF THE PLAN The purpose of the Plan is to promote the interests of the Company by: (a) attracting and retaining persons of outstand |
|
| July 31, 2017 |
S-8 1 a17-186302s8.htm S-8 As filed with the Securities and Exchange Commission on July 31, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 NOVELION THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction of ( |
|
| July 31, 2017 |
NOVELION THERAPEUTICS INC. 2017 EMPLOYEE STOCK PURCHASE PLAN Exhibit 99.1 NOVELION THERAPEUTICS INC. 2017 EMPLOYEE STOCK PURCHASE PLAN 1. Defined Terms Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and sets forth certain operational rules related to those terms. 2. Purpose of Plan The Plan is intended to enable Eligible Employees of the Company and its Designated Subsidiaries to use payroll deductions to purchase shar |
|
| July 31, 2017 |
As filed with the Securities and Exchange Commission on July 31, 2017 Registration No. |
|
| June 30, 2017 |
CUSIP No. 67001K202 Page 1 of 7 Pages SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Novelion Therapeutics Inc. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboa |
|
| June 29, 2017 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorporation) ( |
|
| June 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 31, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorporation) (C |
|
| June 1, 2017 |
Exhibit 99.1 Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D Vancouver, British Columbia & Cambridge, June 1, 2017 ? Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of John J. Orloff, M.D. to it |
|
| May 23, 2017 |
NVLN / NOVELION THERAPEUTICS INC. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 11, 2017 |
DEFA14A 1 a17-119344defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Pr |
|
| May 9, 2017 |
Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 9, 2017 |
Exhibit Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ? Agreement ?) is made and entered into as of this 8th day of May, 2017, by and between (1) Novelion Services USA, Inc., a Delaware corporation (the ? Company ?) and, solely with respect to Sections 2, 9(a) and 12 hereof, Aegerion Pharmaceuticals, Inc. (? Aegerion ?), on the one hand, and (2) Mary T. Szela (the ? Employee ?) |
|
| May 9, 2017 |
STRICTLY PERSONAL AND CONFIDENTIAL Exhibit Exhibit 10.2 [Date] STRICTLY PERSONAL AND CONFIDENTIAL [Name] [Address] Dear [Name]: Re: Amendments to your Employment Agreement Further to our recent discussions, this letter sets out our proposal to amend the terms your employment with Novelion Services USA, Inc. (? Novelion Services ?). This letter is referred to as the Amendment Agreement. Novelion Services proposes the following amend |
|
| May 9, 2017 |
AMENDED AND RESTATED SUPPLEMENTAL INDENTURE Exhibit Exhibit 4.1 AMENDED AND RESTATED SUPPLEMENTAL INDENTURE This Amended and Restated Supplemental Indenture (this ? Restated Supplemental Indenture ?) is dated as of May 8, 2017, by and among Aegerion Pharmaceuticals, Inc., a Delaware corporation (the ? Company ?), Novelion Therapeutics Inc. (f/k/a QLT Inc.), a British Columbia corporation (? Novelion ?), and The Bank of New York Mellon Trust |
|
| May 9, 2017 |
Exhibit Exhibit 99.1 Novelion Therapeutics Reports First Quarter 2017 Financial Results ? Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer ? Defined Clinical Development Plan for Zuretinol Following Positive FDA Meeting ? Company Reiterates FY 2017 Total Net Revenues Guidance Between $155 and $165 million ? Conference call to be held today at 8:30 a.m. ET VANCOUVER, B |
|
| May 9, 2017 |
Qlt 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorpora |
|
| May 1, 2017 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 1, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Novelion Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) April 19, 2017 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| April 19, 2017 |
Qlt 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 19, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorp |
|
| April 19, 2017 |
Novelion Therapeutics’ Request to Voluntarily Delist from the Toronto Stock Exchange Granted Exhibit Exhibit 99.1 Novelion Therapeutics? Request to Voluntarily Delist from the Toronto Stock Exchange Granted Vancouver, BC, April 19, 2017 - Novelion Therapeutics, Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that, as part of its cost rationalization process, the Company?s |
|
| April 13, 2017 |
Exhibit Exhibit 16.1 April 12, 2017 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read the statements made by Novelion in Item 4.01 of Novelion Therapeutics Inc.?s Current Report on Form 8-K dated April 11, 2017, and we agree with the statements concerning our Firm in such Form 8-K. Yours truly, /s/ DELOITTE LLP Chartered Professional Ac |
|
| April 13, 2017 |
Qlt 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 11, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorp |
|
| April 5, 2017 |
Qlt AMENDMENT NO. 5 TO THE SCHEDULE 13D (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 5)1 Novelion Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 67001K 20 2 (CUSIP Number) STEVE WOLOSKY, ESQ. O |
|
| March 31, 2017 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 30, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorp |
|
| March 31, 2017 |
Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors Exhibit Exhibit - 99.1 Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors Vancouver, British Columbia, March 31, 2017 - Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effe |
|
| March 31, 2017 |
Exhibit 24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Benjamin Harshbarger, Gregory Perry, Paul Kinsella and Jennifer Fitzpatrick, signing singly, as the undersigned?s true and lawful attorneys-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U. |
|
| March 30, 2017 |
Document U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-17082 Novelion Therapeu |
|
| March 30, 2017 |
EXHIBIT 10.23 NOVELION THERAPEUTICS INC. NOVELION 2016 EQUITY INCENTIVE PLAN STOCK OPTION AWARD GRANT NOTICE AND STOCK OPTION AWARD AGREEMENT (Employees) Novelion Therapeutics Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee”), an award (“Award”) of an option (“Option”) to purchase a |
|
| March 30, 2017 |
[Remainder of this page intentionally left blank] EXHIBIT 10.46 Novelion Services USA, Inc. 2711 Centerville Road Suite 400 Wilmington, DE 19808 November 28, 2016 Ben Harshbarger c/o Aegerion Pharmaceuticals, Inc. One Main Street Suite 800 Cambridge, MA 02142 Dear Ben: RE: Offer of Employment As you are aware, Aegerion Pharmaceuticals, Inc. (“Aegerion”), QLT Inc. and Isotope Acquisition Corp. have agreed to carry out a merger (the “Merger”) on th |
|
| March 30, 2017 |
[Remainder of this page intentionally left blank] EXHIBIT 10.37 Novelion Services USA, Inc. 2711 Centerville Road Suite 400 Wilmington, DE 19808 November 28, 2016 Gregory Perry c/o Aegerion Pharmaceuticals, Inc. One Main Street Suite 800 Cambridge, MA 02142 Dear Greg: RE: Offer of Employment As you are aware, Aegerion Pharmaceuticals, Inc. (“Aegerion”), QLT Inc. and Isotope Acquisition Corp. have agreed to carry out a merger (the “Merger”) on the |
|
| March 30, 2017 |
Exhibit 10.22 NOVELION THERAPEUTICS INC. NOVELION 2016 EQUITY INCENTIVE PLAN STOCK OPTION AWARD GRANT NOTICE AND STOCK OPTION AWARD AGREEMENT (Directors) Novelion Therapeutics Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee”), an award (“Award”) of an option (“Option”) to purchase a |
|
| March 30, 2017 |
Exhibit 10.26 NOVELION THERAPEUTICS INC. NOVELION 2016 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AWARD AGREEMENT Novelion Therapeutics Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee”), an award (“Award”) consisting of the number of rest |
|
| March 30, 2017 |
EX-10.27 10 nvln-12312016xex1027.htm EXHIBIT 10.27 Exhibit 10.27 INDEMNITY AGREEMENT This AGREEMENT made effective as of the th day of , 201 BETWEEN: NOVELION THERAPEUTICS INC., a British Columbia company having a principal place of business at 887 Great Northern Way, Suite 101, Vancouver, British Columbia, Canada V5T 4T5 (the “Company”) AND: , a Director of the Company, of (the “Indemnitee”) WHER |
|
| March 30, 2017 |
[Remainder of this page intentionally left blank] EXHIBIT 10.47 Novelion Services USA, Inc. 2711 Centerville Road Suite 400 Wilmington, DE 19808 November 28, 2016 Roger Louis c/o Aegerion Pharmaceuticals, Inc. One Main Street Suite 800 Cambridge, MA 02142 Dear Roger: RE: Offer of Employment As you are aware, Aegerion Pharmaceuticals, Inc. (“Aegerion”), QLT Inc. and Isotope Acquisition Corp. have agreed to carry out a merger (the “Merger”) on the |
|
| March 30, 2017 |
SUBLEASE AMENDING AND EXPANSION AGREEMENT 887 Great Northern Way, Vancouver Exhibit 10.7 SUBLEASE AMENDING AND EXPANSION AGREEMENT 887 Great Northern Way, Vancouver THIS AGREEMENT, dated for reference the 4th day of January, 2016, but effective the 1st day of January, 2016 (the “Effective Date”), BETWEEN: DISCOVERY PARKS REALTY CORP (the "Sublandlord") AND: QLT INC. (the "Subtenant") WITNESSES THAT WHEREAS: A. By a lease (the "Head Lease") executed as of the 5th day of Ap |
|
| March 30, 2017 |
[Remainder of this page intentionally left blank] Exhibit 10.48 Novelion Services USA, Inc. 2711 Centerville Road Suite 400 Wilmington, DE 19808 November 28, 2016 Remi Menes c/o Aegerion Pharmaceuticals, Inc. One Main Street Suite 800 Cambridge, MA 02142 Dear Remi: RE: Offer of Employment As you are aware, Aegerion Pharmaceuticals, Inc. (“Aegerion”), QLT Inc. and Isotope Acquisition Corp. have agreed to carry out a merger (the “Merger”) on the te |
|
| March 30, 2017 |
Exhibit 10.6 SUBLEASE THIS SUBLEASE dated for reference June 2, 2015, BETWEEN: DISCOVERY PARKS REALTY CORP. (the “Sublandlord”) AND: QLT INC. (the “Subtenant”) WHEREAS: A.By a lease (the “Head Lease”) executed as of the 5th day of April, 2013, a copy of which is annexed hereto as Schedule “A”, Dundee Properties Limited Partnership and 560677 B.C. Ltd. (together, the “Head Landlord”) leased to Disc |
|
| March 30, 2017 |
Exhibit 10.25 NOVELION THERAPUETICS INC. NOVELION 2016 EQUITY INCENTIVE PLAN PERFORMANCE RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND PERFORMANCE RESTRICTED STOCK UNIT AWARD AGREEMENT Novelion Therapeutics Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee”), an award (“Award”) consisti |
|
| March 30, 2017 |
Exhibit 10.24 NOVELION THERAPEUTICS INC. NOVELION 2016 EQUITY INCENTIVE PLAN STOCK OPTION AWARD GRANT NOTICE AND STOCK OPTION AWARD AGREEMENT (Executives) Novelion Therapeutics Inc. (the “Company”), pursuant to its 2016 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Grantee”), an award (“Award”) of an option (“Option”) to purchase a |
|
| March 30, 2017 |
SUBLEASE RENEWAL AGREEMENT 887 Great Northern Way, Vancouver Exhibit 10.8 SUBLEASE RENEWAL AGREEMENT 887 Great Northern Way, Vancouver THIS AGREEMENT, dated the 18th day of May, 2016 (the “Effective Date”), BETWEEN: DISCOVERY PARKS REALTY CORP. (the “Sublandlord”) AND: QLT INC. (the “Subtenant”) WITNESSES THAT WHEREAS: A.By a lease (the “Head Lease”) executed as of the 5th day of April, 2013, Dundee Properties Limited Partnership and 560677 B.C. Ltd. (toget |
|
| March 30, 2017 |
Exhibit 10.28 INDEMNITY AGREEMENT This AGREEMENT made effective as of the 29th day of November, 2016. BETWEEN: NOVELION THERAPEUTICS INC., a British Columbia company having a principal place of business at 887 Great Northern Way, Vancouver, British Columbia, Canada V5T 4T5 (the “Company”) AND: , an Officer of the Company, of (the “Indemnitee”) WHEREAS, it is essential to the Company to retain and |
|
| March 30, 2017 |
SUBSIDIARIES OF NOVELION THERAPEUTICS INC. Exhibit 21.1 SUBSIDIARIES OF NOVELION THERAPEUTICS INC. Entity Name Jurisdiction of Organization or Incorporation Aegerion Pharmaceuticals, Inc. Delaware Aegerion Pharmaceuticals Ltd. Bermuda Aegerion Pharmaceuticals (Canada) Ltd. Canada Aegerion Pharmaceuticals Holdings, Inc. Delaware Aegerion Mexico, S. DE R.L. DE C.V. Mexico Aegerion Argentina S.R.L. Argentina Aegerion Pharmaceuticals K.K. Japa |
|
| March 15, 2017 |
Qlt 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorpo |
|
| March 15, 2017 |
Exhibit Exhibit 99.1 Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results - Company Reiterates FY 2017 Total Net Product Sales Expected to be Between $155 and $165 million - Global Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, March 15, 2017 - Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical compan |
|
| March 15, 2017 |
EX-99.2 3 nvln-12312016rfsandlps992.htm EXHIBIT 99.2 Exhibit 99.2 Risk Factors Risks Associated with Product Development and Commercialization Our business depends on the success of metreleptin and lomitapide. We may not be able to meet expectations with respect to sales of these products and revenues from such sales and if we are not able to meet such expectations, we may not be able to attain or |
|
| March 13, 2017 |
Document SEC FILE NUMBER 000-17082 CUSIP NUMBER 67001K202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 7, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorporation) ( |
|
| March 7, 2017 |
U.S. Patent Trial and Appeal Board Affirms Lomitapide Patents with Favorable IPR Decisions Exhibit 99.1 U.S. Patent Trial and Appeal Board Affirms Lomitapide Patents with Favorable IPR Decisions Vancouver, British Columbia & Cambridge, MA, March 7, 2017 ? Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the United States Patent Trial and Appeal |
|
| February 14, 2017 |
NVLN / NOVELION THERAPEUTICS INC. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Novelion Therapeutics Inc. (Name of Issuer) Common stock, without par value (Title of Class of Securities) 67001K202 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2017 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them to Schedule 13G (including additional amendments thereto) with respect to the Common Shares, without par value, of Novelion Therapeutics Inc. This Joint Filing Agreement shall be filed as an Exhibi |
|
| February 14, 2017 |
NVLN / NOVELION THERAPEUTICS INC. / SCOPIA CAPITAL MANAGEMENT LP - SCHEDULE 13G Passive Investment SC 13G 1 e73026-13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Novelion Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 67001K103 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| January 9, 2017 |
Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook Exhibit Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook ? Company Reports Preliminary Total Net Product Sales Expected to be Between $150 million and $152 million, Exceeding High End of Prior Guidance ? Global Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, January 9, 2017 - Novelion Therapeutics Inc. |
|
| January 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2017 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incor |
|
| December 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2016 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) British Columbia, Canada 000-17082 N/A (State or Other Jurisdiction of Incorporatio |
